inRegen’s technology has the potential to restore kidney function by using the patient’s own (autologous) kidney cells. By contrast, organ transplantation from other donors (allogenic transplants) can be associated with organ rejection and failure. Further, the patient lives with the adverse effects of immunosuppression.
inRegen's patented technology uses multiple breakthroughs in the manufacturing automation, supply chain and medical delivery of cellular therapy products. While it has long been held that the body contains cells with regenerative power, inRegen's technology is able to identify these cells and harness them to restore function lost from chronic diseases.
inRegen’s kidney restoration process begins when a small biopsy of the disease kidney is sent to inRegen. inRegen is able to identify the patient’s own healthy progenitor cells, and formulate them into a personalized product that can be re-injected into the damaged kidney for repair and restoration of function. When the manufactured Renal Advanced Cell Therapy (REACT) is injected into the diseased kidney, it is programmed to integrate into the damaged tissues and restore function by controlling inflammation, fibrosis and angiogenesis to form new functioning tissues and ultimately, a more healthy kidney.
SAFETY & RESPONSIBILITY
Clinical Trials conducted to date
The Neo-Kidney Augment appears to be well tolerated in patients injected to date. There have been no identified adverse reactions shown to be related to the kidney augmenting product.